pSivida Corp. (PSDV)

2.22
0.06 2.42
NASDAQ : Health Technology
Prev Close 2.27
Open 2.26
Day Low/High 2.13 / 2.27
52 Wk Low/High 0.93 / 2.88
Volume 300.85K
Avg Volume 358.80K
Exchange NASDAQ
Shares Outstanding 45.16M
Market Cap 51.94M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
PSivida CEO To Discuss Company’s Sustained Release Delivery System For Biologics At Two Upcoming Conferences

PSivida CEO To Discuss Company’s Sustained Release Delivery System For Biologics At Two Upcoming Conferences

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida’s president and chief executive officer, Dr.

PSivida Announces Resubmission Of New Drug Application For ILUVIEN®

PSivida Announces Resubmission Of New Drug Application For ILUVIEN®

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment...

PSivida Corp. Announces $7.0 Million Investment By RA Capital

PSivida Corp. Announces $7.0 Million Investment By RA Capital

pSivida Corp. (NASDAQ: PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that RA Capital has entered into a securities purchase...

PSivida Announces ILUVIEN® For DME Accepted By National Health Service Scotland

PSivida Announces ILUVIEN® For DME Accepted By National Health Service Scotland

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted...

PSivida Corp. Reports Second Quarter 2014 Results

PSivida Corp. Reports Second Quarter 2014 Results

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31,...

pSivida CEO to Present at 16th Annual BioCEO & Investor Conference February 11

pSivida CEO to Present at 16th Annual BioCEO & Investor Conference February 11

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that Dr.

PSivida Corp Announces Second Quarter 2014 Financial Results Release Date And Conference Call Information

PSivida Corp Announces Second Quarter 2014 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal...

3 Stocks Under $10 Moving Higher

3 Stocks Under $10 Moving Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

First Week of February 22nd Options Trading For pSivida (PSDV)

First Week of February 22nd Options Trading For pSivida (PSDV)

Investors in pSivida Corp saw new options become available this week, for the February 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PSDV options chain for the new February 22nd contracts and identified the following call contract of particular interest.

PSivida Corp. Reports First Orders For ILUVIEN® Shipped For U.K. National Health Service Hospitals Less Than Seven Weeks After Final NICE Guidance

PSivida Corp. Reports First Orders For ILUVIEN® Shipped For U.K. National Health Service Hospitals Less Than Seven Weeks After Final NICE Guidance

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has shipped initial orders...

PSDV Crosses Above Key Moving Average Level

PSDV Crosses Above Key Moving Average Level

In trading on Thursday, shares of pSivida Corp crossed above their 200 day moving average of $3.16, changing hands as high as $4.88 per share. pSivida Corp shares are currently trading up about 44.4% on the day.

PSivida Corp. Reports FDA Labeling Discussions For ILUVIEN® For DME; Advisory Committee Meeting No Longer Necessary

PSivida Corp. Reports FDA Labeling Discussions For ILUVIEN® For DME; Advisory Committee Meeting No Longer Necessary

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has entered into labeling...

PSivida Executives To Present At Two Upcoming Investor Conferences This Month

PSivida Executives To Present At Two Upcoming Investor Conferences This Month

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that company management will present at two upcoming investor...

PSivida Reports ILUVIEN® To Be Funded By UK’s National Health Service For Treatment Of Pseudophakic Chronic DME Patients Following Issuance Of Final NICE Guidance

PSivida Reports ILUVIEN® To Be Funded By UK’s National Health Service For Treatment Of Pseudophakic Chronic DME Patients Following Issuance Of Final NICE Guidance

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that on November 27, 2013, the United Kingdom’s National ...

PSivida Corp. Reports First Quarter 2014 Results

PSivida Corp. Reports First Quarter 2014 Results

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its first quarter ended September 30,...

PSivida Corp Announces First Quarter 2014 Financial Results Release Date And Conference Call Information

PSivida Corp Announces First Quarter 2014 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the first quarter of...

First Week Of PSDV December 21st Options Trading

First Week Of PSDV December 21st Options Trading

Investors in pSivida Corp saw new options become available this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PSDV options chain for the new December 21st contracts and identified the following put contract of particular interest.

Alimera, pSivida Eye Drug Rejected by FDA

Alimera, pSivida Eye Drug Rejected by FDA

FDA asks Alimera to conduct another clinical trial of Iluvien before re-submitting for approval.

PSivida Reports Complete Response Letter From FDA For ILUVIEN®

PSivida Reports Complete Response Letter From FDA For ILUVIEN®

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that its licensee Alimera...

PSivida Announces That U.K.’s NICE Recommends ILUVIEN® For Chronic Diabetic Macular Edema In Pseudophakic Eyes; NHS Reimbursement Expected To Follow

PSivida Announces That U.K.’s NICE Recommends ILUVIEN® For Chronic Diabetic Macular Edema In Pseudophakic Eyes; NHS Reimbursement Expected To Follow

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that the United ...

PSivida To Present At 4th Annual Conference On Biosimilars & Biobetters

PSivida To Present At 4th Annual Conference On Biosimilars & Biobetters

pSivida Corp. (NASDAQ: PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, will present at the 4 th Annual Biosimilars &...

PSivida Corp. Reports Fourth Quarter And Fiscal Year 2013 Results

PSivida Corp. Reports Fourth Quarter And Fiscal Year 2013 Results

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal...

PSivida Corp. Announces Fourth Quarter And Fiscal Year 2013 Financial Results Release Date And Conference Call Information

PSivida Corp. Announces Fourth Quarter And Fiscal Year 2013 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the fourth quarter and...

6 Stocks Moving on Unusual Volume

6 Stocks Moving on Unusual Volume

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility.

PSivida To Present At Two Investment Conferences In September

PSivida To Present At Two Investment Conferences In September

pSivida Corp. (NASDAQ: PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, will present at two upcoming investor conferences in...

Alimera, pSivida Eye Drug Warrants FDA Approval On Third Try

Alimera, pSivida Eye Drug Warrants FDA Approval On Third Try

Restricting the type of patient to receive Iluvien should be enough to satisfy FDA safety concerns.

PSivida CEO To Discuss Sustained Delivery Of Antibodies In Ophthalmology And Systemic Disease At International Symposium On Integrated Functionalities

PSivida CEO To Discuss Sustained Delivery Of Antibodies In Ophthalmology And Systemic Disease At International Symposium On Integrated Functionalities

pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, has announced that pSivida President and Chief Executive...

PSivida Announces France’s Transparency Commission Issues Positive Opinion For Reimbursement Of ILUVIEN

PSivida Announces France’s Transparency Commission Issues Positive Opinion For Reimbursement Of ILUVIEN

pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that the Transparency Commission...

PSivida Announces Pricing Of $10.8 Million Offering Of Common Stock

PSivida Announces Pricing Of $10.8 Million Offering Of Common Stock

pSivida Corp. (Nasdaq: PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for the treatment of back-of-the-eye diseases, today announced that it has priced an underwritten...

PSivida Announces Proposed Public Offering Of Common Stock

PSivida Announces Proposed Public Offering Of Common Stock

pSivida Corp. (Nasdaq: PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for the treatment of back-of-the-eye diseases, today announced that it intends to offer and sell...